Article

Bone Scan Index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases

2023-03-01

Abstract excerpt

<h4>Background: </h4> Reports of Bone Scan Index (BSI) calculations as imaging biomarkers to predict survival in patients with metastatic castration-resistant prostate cancer (mCRPC) have been mainly from retrospective studies. To evaluate the effectiveness of enzalutamide (ENZ) in Japanese patients with mCRPC and bone metastases using BSI (bone scintigraphy) and circulating tumor cell (CTC) analysis. Methods Pro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d0d08485-e121-524f-b4b2-4ce208d8b693
DOI: 10.21203/rs.3.rs-2581500/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Bone Scan Index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesDOI 10.21203/rs.3.rs-2581500/v1Read

Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.Semantic proximity Read

Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by EnzalutamideSemantic proximity Read

Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity Read

Bone Pain Is Associated with Short Radiologic-Progression-Free Survival in Patients with Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read

Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate CancerSemantic proximity Read

Analysis of the Role of Alkaline Phosphatase and Gleason Score in Predicting Prognosis and Risk of Bone Metastasis in Prostate CancerSemantic proximity Read

Real-world safety and relative dose intensity of upfront enzalutamide in metastatic castration-sensitive prostate cancerSemantic proximity Read

The Effect of Bone-Modifying Agents on Post-Bone Metastasis SurvivalSemantic proximity Read

Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysisSemantic proximity Read

Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate RadiopharmaceuticalsSemantic proximity Read

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsSemantic proximity Read

FOXI3 Promotes Migration and Proliferation in Prostate Cancer Bone Metastases, Modulated by FGF8Semantic proximity Read